Epstein-barr virus antibodies and uses thereof
AssigneeCity of Hope
InventorsJavier Gordon OGEMBO, Lorraine Zvichapera MUTSVUNGUMA
Life of this patent
Estimating the term…
Loading patent…
AssigneeCity of Hope
InventorsJavier Gordon OGEMBO, Lorraine Zvichapera MUTSVUNGUMA
Estimating the term…
Disclosed herein are antibodies or immunogenic fragments thereof that specifically bind to Epstein-Barr virus (EBV) glycoprotein 350 (gp350) or 220 or one or more immunogenic peptides. Also disclosed are immunogenic peptides comprising fragments of gp350 amino acid sequence, EBV antibody-small molecule conjugates and pharmaceutical compositions comprising the antibody or an immunogenic fragment thereof, one or more immunogenic peptides, or the EBV antibody-small molecule conjugate. The antibodies, immunogenic peptides, conjugates, and pharmaceutical compositions can be used to treat or prevent EBV infections and EBV-associated conditions and diseases.
An antibody or an immunogenic fragment thereof that specifically binds to Epstein-Barr virus (EBV) glycoprotein (gp) 350 or glycoprotein 220.
An immunogenic peptide comprising one or more fragments of gp350, wherein each fragment has an amino acid sequence identical to or sharing at least 60% similarity to residues 1-101, 102-201, or 402-501 of SEQ ID NO:
An antibody-small molecule conjugate comprising:
13-16. (canceled)
20-24. (canceled)
26-29. (canceled)
Dependencies are inferred from the claim text.